UTMD

Business Context and Reporting Period

Company: Utah Medical Products Inc. (UTMD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: UTMD manufactures and markets specialty medical devices, including obstetrics, gynecology, electrosurgery, urology, neonatal, and blood pressure monitoring products. The company operates as a single segment with manufacturing and trading operations in the U.S., Ireland, UK, Australia, and Canada.

Key Financial Metrics

Note: All financial figures are in thousands, except per share amounts.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 10.2% year-over-year. The decline was driven primarily by the loss of the company's largest distributor in China (blood pressure monitoring kits) and an OEM customer (PendoTECH), which accounted for $857 of the prior year's sales. Domestic sales remained relatively flat, while Outside U.S. (OUS) sales dropped 23.4%.
• Margin Expansion: Despite lower sales, Gross Profit Margin improved to 60.6% from 57.0%. This was due to a favorable product mix (loss of low-margin China sales) and a one-time annual adjustment to standard costs that increased inventory value.
• Operating Expenses: Total operating expenses increased by $332 (13.9%). Key drivers included a $127 increase in litigation fees related to Filshie clip product liability lawsuits, a $147 increase in U.S. employee health care costs, and foreign currency translation effects.
• Net Income: Net income declined 14.4% to $2.6 million. The effective tax rate decreased to 18.2% from 21.2%, partially offsetting the decline in pre-tax income.
• Liquidity: Cash and investments increased by $1.6 million quarter-over-quarter to $87.4 million. The company remains debt-free.

Guidance, Outlook, and Risks

• Management Outlook: Management expects 2026 results to be consistent with projections made in the 2025 10-K. Key objectives include realizing new sales of high-pressure process control transducers, regaining OUS business hindered by trade policies, and concluding Filshie clip litigation favorably.
• Capital Allocation: The company intends to continue returning cash to shareholders via dividends and share repurchases when the stock price is deemed undervalued. In Q1 2026, the company repurchased 2,196 shares and paid $989 in dividends.
• Risks and Contingencies:
  • Litigation: Ongoing product liability lawsuits regarding the Filshie Clip System. Management does not expect the outcome to be material to consolidated financial results but noted increased legal fees in Q1.
  • Foreign Exchange: Operations in multiple currencies (EUR, GBP, AUD, CAD) expose the company to exchange rate fluctuations. A weaker USD in Q1 2026 negatively impacted reported OUS sales and increased the USD value of foreign expenses.
  • Customer Concentration: The loss of the China distributor and PendoTECH highlights reliance on specific large customers, though the company is pursuing new biopharmaceutical customers.

Investor Verification Checklist

• Revenue Sustainability: Verify the status of replacement sales for the lost China distributor and PendoTECH OEM business to ensure the 10% revenue decline is not permanent.
• Litigation Exposure: Monitor the progress of the Filshie Clip product liability lawsuits, as legal fees increased significantly in Q1 and could impact future operating income.
• Inventory Levels: Review the $787 increase in inventory (to $8.7 million) to ensure it aligns with expected demand recovery and does not signal future write-downs.
• Health Care Costs: Assess the volatility of self-insured U.S. health care costs, which spiked $147 in Q1, and their potential impact on future G&A expenses.
• Share Repurchase Strategy: Confirm the company's continued commitment to share buybacks given the strong cash position ($87.4 million) and lack of debt.